Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 26, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details a change in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Date of Movement: August 25, 2005
- Previous Holding: 18,454,171 ADRs
- New Holding: 18,413,433 ADRs
- Net Change: Decrease of 40,738 ADRs
- Average Price: $48.29
This change resulted from a movement in the fund. Two directors, Dr. J P Garnier and Dr. T Yamada, are noted as potentially interested in the shares held in the fund in the same capacity as other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a notification of a specific transaction under Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Verify the impact of the 40,738 ADR reduction on the total beneficial ownership of the GlaxoSmithKline US Retirement Savings Plan.
- Confirm the specific roles of Dr. J P Garnier and Dr. T Yamada regarding their potential interest in the fund's holdings.
- Note that this filing does not contain financial performance data for the period.